Publication date: Dec 01, 2019
Palliative care is encountering an increasing number of patients with opioid use disorder who are managed on medication-assisted treatment. Buprenorphine is US Food and Drug Administration approved for office-based management of opioid use disorder. As a partial opioid agonist, it can be used to manage pain in the palliative care setting but can also pose inherent challenges to the management of pain that necessitates full opioid agonists. This article uses a case example to highlight the management of substance use disorder and pain in a patient on buprenorphine along the full illness trajectory. In addition, an overview of buprenorphine pharmacology, unique aspects of the prescribing waiver, and pain management will be discussed.
Jones, K.F. Buprenorphine Use in Palliative Care. 04301. 2019 J Hosp Palliat Nurs (21):6.
|disease||MESH||substance use disorder|
- BRIDGE Device for Treatment of Opioid Withdrawal
- Stigma as a fundamental hindrance to the United States opioid overdose crisis response.
- Making the business case for an addiction medicine consult service: a qualitative analysis.
- Managing Opioids, Including Misuse and Addiction, in Patients With Serious Illness in Ambulatory Palliative Care: A Qualitative Study.
- Provider Misinterpretation, Documentation, and Follow-Up of Definitive Urine Drug Testing Results.